Coign Capital Advisors LLC Buys Shares of 777 Eli Lilly and Company (NYSE:LLY)

Coign Capital Advisors LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 777 shares of the company's stock, valued at approximately $600,000.

A number of other institutional investors have also modified their holdings of LLY. CWA Asset Management Group LLC lifted its position in shares of Eli Lilly and Company by 11.9% in the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after buying an additional 724 shares during the last quarter. Centerpoint Advisory Group acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $514,000. M&T Bank Corp lifted its holdings in Eli Lilly and Company by 0.7% in the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock worth $236,389,000 after acquiring an additional 1,867 shares during the last quarter. Kentucky Trust Co acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $834,000. Finally, Proficio Capital Partners LLC grew its holdings in shares of Eli Lilly and Company by 30.2% during the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after purchasing an additional 1,562 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Guggenheim cut their target price on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research note on Monday. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,012.00.

Remove Ads

Eli Lilly and Company Trading Down 0.0 %

Shares of Eli Lilly and Company stock traded down $0.19 during trading on Tuesday, hitting $754.16. The stock had a trading volume of 1,078,098 shares, compared to its average volume of 3,377,721. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a 50 day simple moving average of $835.24 and a 200 day simple moving average of $822.00. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $715.07 billion, a PE ratio of 64.40, a P/E/G ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.